Ipamorelin dosage, as the studies report it — not as a protocol

Read this first

This page reports the Ipamorelin dosage figures that appear in published studies, in the third person — "this dose was given to this species by this route." It is not a protocol, not a recommendation, and there is no human dose to recommend: ipamorelin is not an approved medicine, and the one human efficacy trial used a hospital IV regimen that did not work ^[3]. The numbers below are useful for understanding the research, and for understanding why the popular at-home "stack" doses are guesses. Two quick anchors a non-scientist can hold onto: the drug clears the body fast (about a 2-hour half-life in people ^[2]), and the GH it triggers comes as a single pulse roughly 40 minutes after a dose ^[2]. Everything else is detail. Nothing here tells you to take anything.

Doses used in published studies

Across the literature, the doses and routes vary widely by species and goal:

• Human PK/PD study: 4.21–140.45 nmol/kg IV over 15 minutes, as single doses ^[2].
• Human Phase 2 ileus trial: 0.03 mg/kg IV twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days ^[4].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneally ^[5].

These are research conditions, often intravenous or in animals, and they do not translate into a human self-administration schedule.

Half-life, clearance, and timing

In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg, with the GH response peaking around 40 minutes (0.67 h) after dosing as a single discrete pulse ^[2]. In rats, plasma clearance is roughly 5-fold lower than that of GHRP-6, indicating greater metabolic stability within the peptide class. The short half-life and discrete-pulse kinetics are exactly why ipamorelin is described as a "pulsing" secretagogue and why researchers pair it with a longer-acting GHRH analog for a more sustained signal.

Routes studied

Ipamorelin has been studied across several routes: intravenous (human PK and the clinical trial; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in community use), intranasal (rodent PK, with roughly 20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable; only engineered, ipamorelin-derived analogs achieved meaningful oral absorption (around 10% in dogs) ^[12]. Route matters: most of the favorable efficacy data come from intravenous or intraperitoneal dosing in animals, not the subcutaneous self-injection seen in off-label use.

How to reconstitute cjc-1295 ipamorelin 5mg

This is a research-handling question, not a clinical instruction, and the literature only supports general peptide-handling notes — not a preparation recipe. Ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. A combined "CJC-1295/ipamorelin 5 mg" vial is a gray-market blended research product, not a standardized pharmaceutical, so its label amounts are not quality-assured. This site does not provide reconstitution volumes or a dosing calculation.

How much cjc-1295 ipamorelin should i take

There is no evidence-based answer, and this site will not invent one. No controlled human trial has ever tested the CJC-1295 + ipamorelin combination for any outcome, so any "how much to take" figure circulating online is extrapolated from single-agent pharmacology and community habit, not from data ^[3][7]. The only human ipamorelin dosing that exists in the literature is the intravenous research regimen above, which is not a self-administration guide. The honest position is that a safe, effective human dose of this stack has not been established.